Chlorpromazine versus clotiapine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Mazhari, Shahrzad ^a   S Goughari, Ali ^b   Esmailian, Saeed ^b   Shah Esmaili, Armita ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOTIAPINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DELUSION; DEPRESSION; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; HALLUCINATION; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SELF CARE; SYSTEMATIC REVIEW; THOUGHT DISORDER;

EID: 84961880469     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011810     Document Type: Article

References (40)

1. Adams CE, Rathbone J, Thornley B, Clarke M, Borrill J, Wahlbeck K, et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine 2005;3:15. [PUBMED: 16229742]
2. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
3. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959]
4. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006329; PUBMED: 17253586]
5. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
6. Amato D. Serotonin in antipsychotic drugs action. Behavioural Brain Research 2015;277:125-35.
7. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment 2007;3(4):495-500. [PUBMED: 19300578]
8. Bazrafshan A, Zare M, Okhovati M, Shamsi Meimandi M. Acetophenazine versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD011662]
9. Berk M, Rathbone J, Mandriota-Carpenter S. Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2]
10. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
11. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
12. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
13. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
14. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
16. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
17. Eslami Shahrbabaki M, Sharafkhani R, Dehnavieh R, Vali L. Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD011709]
18. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
19. Geller V, Gorzaltsan I, Shleifer T, Belmaker RH, Bersudsky Y. Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research 2005;80(2-3):343-7. [PUBMED: 16126373]
20. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 51 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
24. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
25. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
26. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
27. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; PUBMED: 18254045]
28. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007778; PUBMED: 19370692]
29. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
30. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry 2012;17:1206-27.
31. Moore NC, Gershon S. Which atypical antipsychotics are identified by screening tests?. Clinical Neuropharmacology 1989;12:167-84.
32. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
33. Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatria Danubina 2014;26 Suppl 1:273-84. [PUBMED: 25413553]
34. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007;64(1):19-28. [PUBMED: 17199051]
35. Saha KB, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010631]
36. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
37. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
38. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
39. Zare M, Bazrafshan A, Okhovati M, Mazhari S, Mousavi R. Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD011655]
40. Zawilska JB, Derbiszewska T, Nowak JZ. Clozapine and other neuroleptic drugs antagonize the light-evoked suppression of melatonin biosynthesis in chick retina: involvement of the D4-like dopamine receptor. Neural Transmission 1994;97:107-17.